GeoVax Labs: From Bullish to Cautious, Execution Risk and Funding Constraints Take Center Stage.

GeoVax Labs' (GOVX) fair value estimate remains stable at $270.83 per share, despite analysts adopting a more cautious tone. Concerns over execution, funding, and fewer near-term catalysts have led to a downgrade to Hold from Buy. The company is advancing its GEO-MVA program, but limited near-term catalysts and tightening capital resources raise execution risk. Analysts recommend monitoring funding clarity and clinical progress.